| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8744899 | Clinical Microbiology and Infection | 2018 | 26 Pages |
Abstract
We found a 3500-fold variation in antibiotic C. difficile MIC50, with aminoglycosides as the least active agents and rifamycins as the most active. Further research is needed to determine how in vitro measures can help assess patient C. difficile risk and guide antimicrobial stewardship.
Related Topics
Life Sciences
Immunology and Microbiology
Microbiology
Authors
N. Khanafer, N. Daneman, T. Greene, A. Simor, P. Vanhems, M. Samore, K.A. Brown,